{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:02:01Z","timestamp":1788271321704,"version":"build-2803163510"},"reference-count":59,"publisher":"China Science Publishing & Media Ltd.","issue":"11","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.3724\/abbs.2022153","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T09:09:36Z","timestamp":1665652176000},"page":"1569-1576","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape"],"prefix":"10.3724","volume":"54","author":[{"given":"Yuyue","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Kocarnik JM","year":"2022","unstructured":"Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, Henrikson HJ. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019. JAMA Oncol, 2022, 8:","journal-title":"JAMA Oncol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"Harding SM","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature, 2017, 548: 466-470.","journal-title":"Nature"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"Huang RX","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther, 2020, 5:","journal-title":"Signal Transduct Target Ther"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2015.09.009","volume":"35","author":"Skvortsova I","year":"2015","unstructured":"Skvortsova I, Debbage P, Kumar V, Skvortsov S. Radiation resistance: cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Semin Cancer Biol, 2015, 35: 39-44.","journal-title":"Semin Cancer Biol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"Rodr\u00edguez-Ruiz ME","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol, 2018, 39: 644-655.","journal-title":"Trends Immunol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1101\/gad.348314.121","volume":"35","author":"Pilger D","year":"2021","unstructured":"Pilger D, Seymour LW, Jackson SP. Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes Dev, 2021, 35: 602-618.","journal-title":"Genes Dev"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"Jackson SP","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature, 2009, 461: 1071-1078.","journal-title":"Nature"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/bjc.2015.281","volume":"113","author":"Pinheiro M","year":"2015","unstructured":"Pinheiro M, Pinto C, Peixoto A, Veiga I, Lopes P, Henrique R, Baldaia H. Target gene mutational pattern in lynch syndrome colorectal carcinomas according to tumour location and germline mutation. Br J Cancer, 2015, 113: 686-692.","journal-title":"Br J Cancer"},{"key":"CITATION9","doi-asserted-by":"crossref","unstructured":"Musich PR, Li Z, Zou Y. Xeroderma pigmentosa group A (XPA), nucleotide excision repair and regulation by ATR in response to ultraviolet irradiation.                                                      Adv Exp Med Biol                         2017, 996: 41-54.","DOI":"10.1007\/978-3-319-56017-5_4"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5306\/wjco.v11.i7.428","volume":"11","author":"Curia MC","year":"2020","unstructured":"Curia MC, Catalano T, Aceto GM. MUTYH: not just polyposis. World J Clin Oncol, 2020, 11: 428-449.","journal-title":"World J Clin Oncol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"Carter HB","year":"2019","unstructured":"Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K. Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urology, 2019, 75: 743-749.","journal-title":"Eur Urology"},{"key":"CITATION12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142158","volume":"131","author":"Deland K","year":"2021","unstructured":"Deland K, Starr BF, Mercer JS, Byemerwa J, Crabtree DM, Williams NT, Luo L. Tumor genotype dictates radiosensitization after ATM deletion in primary brainstem glioma models. J Clin Invest, 2021, 131:","journal-title":"J Clin Invest"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","volume":"150","author":"Bi Y","year":"2018","unstructured":"Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C. Radiosensitization by the PARP inhibitor Olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. Gynecol Oncol, 2018, 150: 534-544.","journal-title":"Gynecol Oncol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3724\/abbs.2022056","volume":"54","author":"Yin J","year":"2022","unstructured":"Yin J, Hu J. The origin of unwanted editing byproducts in gene editing. Acta Biochim Biophys Sin, 2022, 54: 767-781.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3724\/abbs.2022050","volume":"54","author":"Wang L","year":"2022","unstructured":"Wang L, Song K, Yu J, Da LT. Computational investigations on target-site searching and recognition mechanisms by thymine DNA glycosylase during DNA repair process. Acta Biochim Biophys Sin, 2022, 54: 796-806.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"Ciccia A","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell, 2010, 40: 179-204.","journal-title":"Mol Cell"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","volume":"160","author":"Gavande NS","year":"2016","unstructured":"Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: the past or future of cancer treatment?. Pharmacol Ther, 2016, 160: 65-83.","journal-title":"Pharmacol Ther"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1093\/nar\/gkv250","volume":"43","author":"Reynolds P","year":"2015","unstructured":"Reynolds P, Cooper S, Lomax M, O\u2032Neill P. Disruption of PARP1 function inhibits base excision repair of a sub-set of DNA lesions. Nucleic Acids Res, 2015, 43: 4028-4038.","journal-title":"Nucleic Acids Res"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"Goldstein M","year":"2015","unstructured":"Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med, 2015, 66: 129-143.","journal-title":"Annu Rev Med"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/carcin\/bgs132","volume":"33","author":"Sousa FG","year":"2012","unstructured":"Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JAP, Larsen AK, Saffi J. PARPs and the DNA damage response. Carcinogenesis, 2012, 33: 1433-1440.","journal-title":"Carcinogenesis"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/ars.2013.5668","volume":"21","author":"Santivasi WL","year":"2014","unstructured":"Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal, 2014, 21: 251-259.","journal-title":"Antioxid Redox Signal"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"Kastan MB","year":"2004","unstructured":"Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature, 2004, 432: 316-323.","journal-title":"Nature"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"16874","DOI":"10.1073\/pnas.1306160110","volume":"110","author":"Goldstein M","year":"2013","unstructured":"Goldstein M, Derheimer FA, Tait-Mulder J, Kastan MB. Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair. Proc Natl Acad Sci USA, 2013, 110: 16874-16879.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3724\/abbs.2022053","volume":"54","author":"Li N","year":"2022","unstructured":"Li N, Chen H, Wang J. DNA damage and repair in the hematopoietic system. Acta Biochim Biophys Sin, 2022, 54: 847-857.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"e1437","DOI":"10.1038\/cddis.2014.415","volume":"5","author":"Chang L","year":"2014","unstructured":"Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH. PI3k\/Akt\/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis, 2014, 5:","journal-title":"Cell Death Dis"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","volume":"17","author":"Buckley AM","year":"2020","unstructured":"Buckley AM, Lynam-Lennon N, O\u2032Neill H, O\u2032Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol, 2020, 17: 298-313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"CITATION27","doi-asserted-by":"crossref","unstructured":"Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening.                                                      Prog Mol Biol Transl Sci                          2017, 151: 1-32.","DOI":"10.1016\/bs.pmbts.2017.07.002"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1074-7613(00)80619-6","volume":"9","author":"Gao Y","year":"1998","unstructured":"Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW. A targeted DNA-PKcs-null mutation reveals DNA-pk-independent functions for KU in V(D)J recombination. Immunity, 1998, 9: 367-376.","journal-title":"Immunity"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","volume":"18","author":"Pierce LJ","year":"2000","unstructured":"Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations. J Clin Oncol, 2000, 18: 3360-3369.","journal-title":"J Clin Oncol"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"Kim G","year":"2015","unstructured":"Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R. FDA approval summary: Olaparib monotherapy in patients with deleterious germline                         BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res, 2015, 21: 4257-4261.","journal-title":"Clin Cancer Res"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","volume":"20","author":"Karnak D","year":"2014","unstructured":"Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB. Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer. Clin Cancer Res, 2014, 20: 5085-5096.","journal-title":"Clin Cancer Res"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"Eikesdal HP","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol, 2021, 32: 240-249.","journal-title":"Ann Oncol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","volume":"24","author":"Ison G","year":"2018","unstructured":"Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res, 2018, 24: 4066-4071.","journal-title":"Clin Cancer Res"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","volume":"124","author":"van Bussel MTJ","year":"2020","unstructured":"van Bussel MTJ, Awada A, de Jonge MJA, Mau-S\u00f8rensen M, Nielsen D, Sch\u00f6ffski P, Verheul HMW. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. Br J Cancer, 2020, 124: 728-735.","journal-title":"Br J Cancer"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.2147\/CMAR.S208720","volume":"11","author":"Munster P","year":"2019","unstructured":"Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy. Cancer Manag Res, 2019, 11: 10463-10476.","journal-title":"Cancer Manag Res"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","volume":"12","author":"Batey MA","year":"2013","unstructured":"Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A. Preclinical evaluation of a novel ATM inhibitor, KU59403,                         in vitro and                         in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther, 2013, 12: 959-967.","journal-title":"Mol Cancer Ther"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"Yap TA","year":"2020","unstructured":"Yap TA, O\u2032Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol, 2020, 38: 3195-3204.","journal-title":"J Clin Oncol"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"Yap TA","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clin Cancer Res, 2021, 27: 5213-5224.","journal-title":"Clin Cancer Res"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"Jiang M","year":"2021","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sin B, 2021, 11: 2983-2994.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"Slade D","year":"2020","unstructured":"Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev, 2020, 34: 360-394.","journal-title":"Genes Dev"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"104210","DOI":"10.1016\/j.bioorg.2020.104210","volume":"104","author":"Wang X","year":"2020","unstructured":"Wang X, Wang Y, Gou S, Chen F. A trifunctional Pt(II) complex alleviates the NHEJ\/HR-related DSBs repairs to evade cisplatin-resistance in NSCLC. BioOrg Chem, 2020, 104:","journal-title":"BioOrg Chem"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.ctrv.2021.102262","volume":"100","author":"Macchini M","year":"2021","unstructured":"Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Cancer Treatment Rev, 2021, 100:","journal-title":"Cancer Treatment Rev"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"Li H","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer, 2020, 19:","journal-title":"Mol Cancer"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"Fugger K","year":"2021","unstructured":"Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G. Targeting the nucleotide salvage factor DNPH1 sensitizes                         BRCA-deficient cells to PARP inhibitors. Science, 2021, 372: 156-165.","journal-title":"Science"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41556-020-00624-3","volume":"23","author":"Verma P","year":"2021","unstructured":"Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, Li W. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. Nat Cell Biol, 2021, 23: 160-171.","journal-title":"Nat Cell Biol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"Pili\u00e9 PG","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol, 2019, 16: 81-104.","journal-title":"Nat Rev Clin Oncol"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3724\/abbs.2022061","volume":"54","author":"Zhang H","year":"2022","unstructured":"Zhang H, Chen Y, Jiang Y, Mao Z. DNA double-strand break repair and nucleic acid-related immunity. Acta Biochim Biophys Sin, 2022, 54: 828-835.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.celrep.2019.09.065","volume":"29","author":"Schadt L","year":"2019","unstructured":"Schadt L, Sparano C, Schweiger NA, Silina K, Cecconi V, Lucchiari G, Yagita H. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep, 2019, 29: 1236-1248.e7.","journal-title":"Cell Rep"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","volume":"80","author":"Reisl\u00e4nder T","year":"2020","unstructured":"Reisl\u00e4nder T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell, 2020, 80: 21-28.","journal-title":"Mol Cell"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.semcancer.2020.08.017","volume":"77","author":"Le Saux O","year":"2021","unstructured":"Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol, 2021, 77: 127-143.","journal-title":"Semin Cancer Biol"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.7150\/thno.24387","volume":"8","author":"Chu Y","year":"2018","unstructured":"Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics, 2018, 8: 4238-4246.","journal-title":"Theranostics"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"Formenti SC","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med, 2018, 24: 1845-1851.","journal-title":"Nat Med"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"e01111","DOI":"10.1002\/cti2.1111","volume":"9","author":"Leng Q","year":"2020","unstructured":"Leng Q, Tarbe M, Long Q, Wang F. Pre\u2010existing heterologous T\u2010cell immunity and neoantigen immunogenicity. Clin Transl Immunology, 2020, 9:","journal-title":"Clin Transl Immunology"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-017-0036-5","volume":"8","author":"Johansson P","year":"2018","unstructured":"Johansson P, Klein-Hitpass L, Choidas A, Habenberger P, Mahboubi B, Kim B, Bergmann A. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. Blood Cancer J, 2018, 8:","journal-title":"Blood Cancer J"},{"key":"CITATION55","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Abdisalaam S, Bhattacharya S, Srinivasan K, Sinha D, Asaithamby A. Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling.                                                       Adv Protein Chem Struct Biol                          2019, 115: 297-324.","DOI":"10.1016\/bs.apcsb.2018.11.004"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1093\/nar\/gkx126","volume":"45","author":"Bhattacharya S","year":"2017","unstructured":"Bhattacharya S, Srinivasan K, Abdisalaam S, Su F, Raj P, Dozmorov I, Mishra R. RAD51 interconnects between DNA replication, DNA repair and immunity. Nucleic Acids Res, 2017, 45: 4590-4605.","journal-title":"Nucleic Acids Res"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"Sheng H","year":"2020","unstructured":"Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer, 2020, 8:","journal-title":"J Immunother Cancer"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1038\/ncomms6166","volume":"5","author":"Ahn J","year":"2014","unstructured":"Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun, 2014, 5:","journal-title":"Nat Commun"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"Vanpouille-Box C","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun, 2017, 8:","journal-title":"Nat Commun"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/B41873BECB17415C84AFE44984F6DF9B","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022153","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/B41873BECB17415C84AFE44984F6DF9B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T06:30:50Z","timestamp":1672122650000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2022153","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}